Brief: IMAC Holdings Reports Completion of Second Cohort of Study of Mesenchymal Stem Cells for Treatment of Bradykinesia
16/02/2022 14:31
Feb 16 (Reuters) - IMAC Holdings Inc IMAC.O :
* IMAC HOLDINGS, INC. ANNOUNCES COMPLETION OF SECOND COHORT
OF ITS
PHASE 1 CLINICAL STUDY OF UMBILICAL CORD-DERIVED MESENCHYMAL
STEM CELLS FOR THE TREATMENT OF BRADYKINESIA DUE TO PARKINSON’S
DISEASE
Source text for Eikon: ID:nGNXbrnQ5V
Further company coverage: IMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imac Holdings
See all newsBrief: Nasdaq To Suspend Imac Holdings Stock Trading On March 26, 2025
Imac Holdings Inc Reports Results For The Quarter Ended September 30: Earnings Summary
Brief: Imac Holdings Inc - Regains Compliance With Nasdaq Audit Committee Rule
Imac Holdings Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: IMAC Holdings Enters Agreement To Issue 4,676 Shares Of Series G Preferred Stock